HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by T’Sjoen, G. G Articles by Gooren, L. Search for Related Content PubMed PubMed Citation Articles by T’Sjoen, G. G Articles by Gooren, L.

Department of Endocrinology, University Hospital Ghent, De Pintelaan 185, 9000 Gent, Belgium
¹ Department of Endocrinology, Free University Amsterdam, 1007 MB, The Netherlands
² Department of Hematology, University of Liège, 4000 Sart Tilman, Belgium

(Requests for offprints should be addressed to G G T’Sjoen; Email: guy.tsjoen{at}ugent.be)

The objective of this investigation was to study the effects of sex steroids on levels of haemoglobin (Hb) and haematocrit (Hct) and to analyse whether these effects can be related to levels of the soluble transferrin receptor (sTfR), a marker of erythropoietic activity. Nineteen male-to-female transsexuals were randomly assigned to either oral ethinyl oestradiol (EE) (n=12) or transdermal 17ß-oestradiol (E2) (n=7); both treatments included the anti-androgen cyproterone acetate (CA). Six male-to-female transsexuals were treated with CA only. Fifteen female-to-male transsexuals were treated with i.m. testosterone esters. The Hct, and levels of Hb, IGF-I, GH and sTfR were measured before and after 4 months of hormone administration. Androgen administration significantly increased the sTfR concentration by 31.5% (P=0.008) and increased levels of Hct, Hb and IGF-I. Both regimens of CA with oral EE and transdermal E2 reduced plasma testosterone similarly to castrate values and decreased Hb and Hct. The CA+oral EE combination induced a decrease in sTfR of 19.0% (P=0.002) which was not the case with CA+transdermal E2 (P=0.27). This cannot be explained by the profound decline in plasma testosterone which was similar with both regimens, but this difference could be related to the different effects of the two regimens on plasma IGF-I. This assumption is supported by the positive correlation that was found to exist between plasma sTfR and IGF-I after the interventions (P<0.05).

This article has been cited by other articles:

				A. D. Coviello, B. Kaplan, K. M. Lakshman, T. Chen, A. B. Singh, and S. Bhasin Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 914 - 919. [Abstract] [Full Text] [PDF]

				G. Hay, H. Refsum, A. Whitelaw, E. L. Melbye, E. Haug, and B. Borch-Iohnsen Predictors of serum ferritin and serum soluble transferrin receptor in newborns and their associations with iron status during the first 2 y of life Am. J. Clinical Nutrition, July 1, 2007; 86(1): 64 - 73. [Abstract] [Full Text] [PDF]